 Johnson & Johnson’s revenues have generally been increasing over the last several years. As of 2019, Johnson & Johnson’s total net income was estimated to be about 15.12 billion U.S. dollars. This is a slight decrease from the previous year when net income was at about 15.3 billion U.S. dollars. Johnson & Johnson has been majorly impacted by tax laws that cost the company about 13.6 billion dollars in 2018. Johnson & Johnson’s revenue overview Johnson & Johnson is a multinational company that is headquartered in New Brunswick, New Jersey, in the United States. The company’s largest business segment is their pharmaceutical segment, but the company also operates in medical devices, diagnostics, and consumer products. Regionally the United States makes up the largest proportion of Johnson & Johnson’s sales, followed by Europe. Johnson & Johnson’s global R&D positioning Johnson & Johnson has been ranked second among global pharmaceutical companies based on their research and development spending in 2018. Johnson & Johns is also ranked among the top three pharmaceutical companies based on the number of drugs developed in-house. Similarly, Johnson & Johnson is ranked among the top three pharmaceutical companies based on the number of drugs in development in 2019. 